Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $7.50.

Several research firms have weighed in on STTK. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Leerink Partners started coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They set an “outperform” rating and a $4.00 price objective on the stock. Finally, HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th.

Institutional Trading of Shattuck Labs

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC grew its stake in shares of Shattuck Labs by 27.6% in the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock worth $243,000 after buying an additional 55,687 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Shattuck Labs during the 1st quarter worth about $81,000. AQR Capital Management LLC boosted its stake in shares of Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Shattuck Labs during the 1st quarter worth about $97,000. Finally, Nuveen LLC purchased a new position in shares of Shattuck Labs during the 1st quarter worth about $50,000. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Trading Up 7.5%

Shares of STTK stock opened at $1.14 on Friday. Shattuck Labs has a 12 month low of $0.69 and a 12 month high of $7.45. The stock has a market cap of $54.60 million, a P/E ratio of -0.75 and a beta of 1.72. The company has a 50 day simple moving average of $0.96 and a two-hundred day simple moving average of $1.12.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. As a group, equities analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current year.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.